Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

RETHINC: REdefining THerapy In Early COPD for the Pulmonary Trials Cooperative

NCT02867761 is registered in ClinicalTrials.gov with University of Michigan as lead sponsor.

NCT NCT02867761
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02867761 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
RETHINC: REdefining THerapy In Early COPD for the Pulmonary Trials Cooperative
Lead sponsor
University of Michigan
Phase
Phase 3
Overall status
Completed
Start date
August 29, 2017
Completion date
July 7, 2021
Enrollment
780 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

copd (chronic obstructive pulmonary disease)